Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 238

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 238
---
 January 1 of each year from January 1, 2021 continuing through January 1, 2030, by the lesser of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) 455,852 shares or (iii) or a lesser number of shares as may be determined by the Board. On January 1, 2025, the Company increased the number of shares available for future grant under the ESPP by 405,547 shares. If purchase rights granted under the ESPP terminate without having been exercised, the shares of our common stock not purchased under such purchase rights will again become available for issuance under the ESPP.As of September 30, 2025, 11,806 shares of common stock were purchased under the ESPP. As of September 30, 2025, there was an aggregate of 1,641,602 shares reserved for future issuance under the ESPP.Stock-Based Compensation Expense Total stock-based compensation expense recorded for employees, directors and non-employees during the three and nine months ended September 30, 2025 and 2024 was as follows (in thousands):THREE MONTHS ENDED SEPTEMBER 30,NINE MONTHS ENDED SEPTEMBER 30,2025202420252024Research and development$992 $4,699 $11,230 $13,225 General and administrative2,994 4,118 10,161 12,447 Total stock-based compensation expense$3,986 $8,817 $21,391 $25,672 

14

8. INCOME (LOSS) PER SHARE

Basic and diluted income (loss) per share of common stock are calculated as follows (in thousands, except share and per share data):THREE MONTHS ENDED SEPTEMBER 30,NINE MONTHS ENDED SEPTEMBER 30,2025202420252024Numerator:Net income (loss) attributable to common stockholders - basic and diluted$(7,280)$(52,956)$110,475 $(141,327)Denominator:Weighted-average shares of common stock outstanding - basic40,623,364 37,590,727 40,598,777 36,463,906 Effect of potentially dilutive stock options— — 424,342 — Effect of potentially dilutive employee stock purchase plan shares—